Loss of exclusivityOctober 2040latest FDA-listed patent expiry
CompanyAADI →See this company's full patent-cliff portfolio
Drug detail
Brand name
FYARRO
Active ingredient
SIROLIMUS
Strength
100MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
Modality
Small molecule
FDA approval
November 2021
Marketing status
RX
Listed patents
Patent
Expires
Type
11497737
October 2040
product
10973806
June 2036
use U-3258
12133844
June 2036
use U-4042
12061183
March 2036
product
10705070
March 2036
product
10206887
April 2030
product
8911786
February 2029
product
Regulatory exclusivity
Code
Expires
ODE-386
November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
FYARRO patent cliff — loss of exclusivity October 2040 | CliffBio